Researchers developed and evaluated a deep learning model for predicting coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS).

Changes in pre-ECMO therapy between the first and second waves of COVID-19 or greater disease severity among patients on ECMO may explain the differences in outcomes, critical care specialists said.

Convalescent plasma reduced mortality in COVID-19 patients with acute respiratory distress syndrome (ARDS) when provided within 5 days of invasive mechanical ventilation, the randomized open-label ...

Treatment with convalescent plasma reduced 28-day mortality among adults undergoing mechanical ventilation for COVID-19-induced acute respiratory distress syndrome, according to results published ...

The ARDS group included SARS-CoV-2 patients who required mechanical ventilation during their ICU stay, whereas the non-ARDS group included COVID-19 patients with mild to moderate symptoms.

Key takeaways: Survival rates following transplantation did not differ between those with COVID-19 related ARDS or pulmonary fibrosis. Both groups also had similar rates of freedom from graft failure.

More Mortality After ECMO COVID-19 changed the survival equation for ARDS patients put on ECMO in an analysis of the National Inpatient Sample (NIS) database.

A total of 25,677 (12.1%) cases of long COVID occurred among reinfected participants and 18,460 (8.7%) long-COVID cases ...

“The potential for ExoFlo to treat patients with ARDS represents an advancement in efforts to reduce morbidity and mortality caused by the serious inflammatory complications of COVID-19.” ...

Drs Matteo Bassetti and Antoni Torres explore the early response to patients with severe COVID-19 and how treatment options have progressed since 2020.

Babies born to unvaccinated people who had COVID-19 may be at greater risk of respiratory distress: Study The results show COVID shots in pregnancy can offer protection, researchers say.